EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cervical cancer incidence in Denmark: Disentangling determinants of time trend

Elsebeth Lynge iD, Jeppe Bennekou Schroll iD, Berit Andersen iD, Kirubakaran Balasubramaniam iD, Anna Poulsgaard Frandsen iD, Else Helene Ibfelt iD, Kirsten Marie Jochumsen iD, Maja Ulrikka Bruun Laustsen, Susanne Nielsen iD, Rouzbeh Salmani iD, Doris Schledermann iD, Petra Birgitta Hall Viborg iD und 3 weitere

International Journal of Cancer · 15.11.2024 · 155 (10) · 1769-1779

DOI: 10.1002/ijc.35081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 14.07.2024. Verfasst von Elsebeth Lynge und 14 weiteren Autor:innen. Beteiligte Einrichtung: Zealand University Hospital, University of Copenhagen, Nykøbing Falster, Denmark. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections, Papillomavirus Vaccines, Early Detection of Cancer. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kræftens Bekæmpelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer is a preventable disease. Nevertheless, stagnation has been seen in incidence rates also in countries with well‐functioning healthcare. On this basis, we investigated associations between control interventions and changes in cervical cancer incidence in Denmark from 2009 to 2022. Data on human papillomavirus (HPV)‐vaccination were retrieved from Staten's Serum Institute; on screening recommendations from Danish Health Authority, on screening performance from Danish Quality Database for Cervical Screening; and on cervical cancer incidence from Nordcan and Danish Cancer Register. We reported coverage with HPV vaccination (1+ dose); coverage with cervical cell samples; number of women with primary HPV tests; proportion of non‐normal cell samples without timely follow‐up; number of conizations; and cervical cancer incidence rates. In 2022, all women aged ≤29 had been offered childhood HPV vaccination with coverage of 80%–90%. By 2020–2022, the cervical cancer incidence rate in women aged 20–29 was 3 per 100,000; at level of disease elimination. In 2017, women aged 70+ were offered a one‐time HPV screening, and by 2020–2022, the old‐age peak in cervical cancer incidence had largely disappeared. From 2009 to 2022, proportion of non‐normal cell samples without timely follow‐up decreased from 20% to 10%, and conventional cytology was largely replaced by SurePath liquid‐based cytology; these factors could explain the steady decrease in cervical cancer incidence rate. Implementation of primary HPV screening in women aged 30–59 in 2021 was reflected in a, probably temporary, increase in the 2022 cervical cancer incidence rate. In conclusion, combined interventions with childhood HPV vaccination; one‐time HPV screening of elderly women; and better management of screening broke previous stagnation in cervical cancer incidence rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsPapillomavirus VaccinesEarly Detection of CancerHumansFemaleDenmarkIncidenceAdultMiddle AgedAgedYoung AdultVaccinationRegistries

Stichwörter der Autor:innen

cancer incidence ratecervical cancerhuman papillomavirus vaccinationscreening time trend

Substanzen

Papillomavirus Vaccines

Autor:innen und Institutionen

  • Zealand University Hospital, University of Copenhagen, Nykøbing Falster, Denmark.
  • Department of Obstetrics and Gynecology, Copenhagen University Hospital, Herlev, Denmark.
  • Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • University Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Research Unit of General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Elsebeth Lynge, Jeppe Bennekou Schroll, Berit Andersen, Kirubakaran Balasubramaniam, Anna Poulsgaard Frandsen, Else Helene Ibfelt, Kirsten Marie Jochumsen, Susanne Nielsen, Rouzbeh Salmani, Doris Schledermann, Petra Birgitta Hall Viborg, Marianne Waldstrøm, George Napolitano, Reza Serizawa

Förderung

  • Kræftens Bekæmpelse

Zitieren

APA

Lynge, E., Bennekou Schroll, J., Andersen, B., Balasubramaniam, K., Poulsgaard Frandsen, A., Ibfelt, E. H., Jochumsen, K. M., Bruun Laustsen, M. U., Nielsen, S., Salmani, R., Schledermann, D., Hall Viborg, P. B., Waldstrøm, M., Napolitano, G., & Serizawa, R. (2024). Cervical cancer incidence in Denmark: Disentangling determinants of time trend. International Journal of Cancer, 155(10), 1769-1779. https://doi.org/10.1002/ijc.35081

Vancouver

Lynge E, Bennekou Schroll J, Andersen B, Balasubramaniam K, Poulsgaard Frandsen A, Ibfelt EH, et al. Cervical cancer incidence in Denmark: Disentangling determinants of time trend. International Journal of Cancer. 2024;155(10):1769-1779. doi:10.1002/ijc.35081

BibTeX
@article{Lynge2024,
  author = {Lynge, Elsebeth and Bennekou Schroll, Jeppe and Andersen, Berit and Balasubramaniam, Kirubakaran and Poulsgaard Frandsen, Anna and Ibfelt, Else Helene and Jochumsen, Kirsten Marie and Bruun Laustsen, Maja Ulrikka and Nielsen, Susanne and Salmani, Rouzbeh and Schledermann, Doris and Hall Viborg, Petra Birgitta and Waldstrøm, Marianne and Napolitano, George and Serizawa, Reza},
  title = {Cervical cancer incidence in Denmark: Disentangling determinants of time trend},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {155},
  number = {10},
  pages = {1769--1779},
  doi = {10.1002/ijc.35081}
}
Kostenlos starten →